Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc is a clinical-stage biotechnology company. The company's principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions. Its technology platform for developing autologous cell therapies is for the treatment of vascular diseases. The group's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of critical limb ischemia.


Recent & Breaking News (TSXV:HEM)

Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

John Ballem  4 hours ago

Hemostemix Announces Unit Private Placement

Newsfile 4 hours ago

Hemostemix (TSXV:HEM) closes second tranche of non-brokered private placement

John Ballem  7 days ago

Hemostemix Announces Closing of Second Tranche of UNIT Private Placement

Newsfile 7 days ago

Hemostemix Announces Closing of UNIT Private Placement

Newsfile June 22, 2022

Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01

Newsfile June 14, 2022

Hemostemix (TSXV:HEM) announces non-brokered private placement

John Ballem  May 20, 2022

Hemostemix Announces Financing

Newsfile May 19, 2022

Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations

Newsfile May 19, 2022

Hemostemix Announces Rick Groome as Special Advisor to The CEO

Newsfile May 16, 2022

Hemostemix Announces Its Intellectual Property is Back Home

Newsfile May 10, 2022

Hemostemix Inc. (TSXV:HEM) closes $2.75M non-brokered debenture offering

John Ballem  April 25, 2022

Hemostemix Announces Closing of $2,750,000

Newsfile April 25, 2022

Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed

Newsfile April 12, 2022

Hemostemix Announces Settlement Agreement

Newsfile March 23, 2022

Hemostemix: Interest Payment on Convertible Debenture

Newsfile March 3, 2022

Hemostemix Announces $2,750,000 Convertible Debenture

Newsfile March 2, 2022

Hemostemix Announces Stock Options Grant

Newsfile March 1, 2022

Hemostemix Announces Closing of UNIT Private Placement

Newsfile February 28, 2022

Your Fountain of Youth trademarked by Hemostemix (TSXV:HEM)

Brieanna McCutcheon  February 14, 2022